Marinus Pharmaceuticals Inc

Marinus Pharmaceuticals — Investor Presentation (August 2024)

37 slides from Marinus Pharmaceuticals's investor presentation, Aug 13, 2024

  1. Slide 1: Corporate Presentation August 2024

    Nasdaq: MRNS @MarinusPharma Photo Credit: Kelly Crews Photography Ryan (center) Living with CDKL5 deficiency disorder Corporate Presentation August 2024

  2. Slide 2: Forward-looking statements

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I To the extent that statements contained in this presentation are not descriptions of historical facts regarding Marinus, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe ha

  3. Slide 3: Ganaxolone Development Pipeline

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I Ganaxolone Development Pipeline 3 Ganaxolone is a positive allosteric GABAA receptor modulator with a well-defined MOA designed to treat patients suffering from seizure disorders. Ganaxolone is designed to modulate both synaptic and extrasynaptic

  4. Slide 4: Ganaxolone Engages Both Synaptic and Extra-synaptic GABAA Receptors

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I Ganaxolone Engages Both Synaptic and Extra-synaptic GABAA Receptors 4 Ganaxolone is a neuroactive steroid that targets binding sites on GABAA receptors that are distinct from the benzodiazepine site and other GABAergic molecules.1-3 Ganaxolone mod

  5. Slide 5: ZTALMY Clinical and Commercial Overview

    ZTALMY® Clinical and Commercial Overview Not for promotional use

  6. Slide 6: ZTALMY Has the Potential to Significantly Advance Epilepsy Treatment

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I ZTALMY® Has the Potential to Significantly Advance Epilepsy Treatment 6 Differentiated MOA addresses unmet need Well-characterized safety profile FDA-approved in CDD Scalable commercial infrastructure supports rapid expansion and adoption Signific

  7. Slide 7: Phase 3 CDD Marigold Trial and Open Label Extension Data

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I 7 Ganaxolone Placebo 0 10 20 30 40 Median Percent Reduction 28-day Frequency of Major Motor Seizures 30.7% 6.9% *Wilcoxon Rank-Sum Test **Hodges-Lehman Estimate of Median Dif erence Patients taking ganaxolone experienced a significant reduction in

  8. Slide 8: ZTALMY Performance Metrics and Growth Drivers

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I ZTALMY® Performance Metrics and Growth Drivers 8 Net product revenue of $8.0M for the second quarter of 2024 87% growth from Q2 2023 Continued strong new patient enrollments Continued growth of new prescribers driving demand Achieved profitability

  9. Slide 9: Significant Near-term Milestones Build on Commercial Success

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I Program Indication 1H 2024 2H 2024 1H 2025 2H 2025 CDKL5 deficiency disorder Achieved profitability* Tuberous sclerosis complex Completed Phase 3 enrollment Phase 3 TrustTSC readout Potential filing for FDA Approval Potential launch Developmental

  10. Slide 10: Driving Global Access of ZTALMY (ganaxolone)

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I Driving Global Access of ZTALMY® (ganaxolone) 10 Europe: Collaboration agreement with Orion Corporation for ganaxolone in CDD, TSC, RSE • Up to €90 million of development, commercial, and sales milestones1 ; tiered royalties in the low double-digi

  11. Slide 11: Tuberous Sclerosis Complex

    Tuberous Sclerosis Complex “Many individuals with TSC continue to experience uncontrolled seizures despite a cocktail of multiple antiepileptic drugs. Because new options are always needed, the TSC community welcomes clinical evaluation of new epilepsy treatments.” - Kari Luther Rosbeck, President &

  12. Slide 12: Tuberous Sclerosis Complex (TSC)

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I Tuberous Sclerosis Complex (TSC) 12 CAUSE • Defect or mutation of TSC1 and/or TSC2 genes INCIDENCE • ~1 in 6,000 live births1 COMMON SYMPTOMS • Seizures, cognitive impairment, behavioral difficulties, skin/kidney/lung abnormalities, etc. EPILEPSY

  13. Slide 13: TSC Phase 2 Trial Results

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I TSC Phase 2 Trial Results 13 * -200 -100 -80 -60 -40 -20 0 20 40 60 80 100 Percent reduction in TSC-associated seizure frequency =median 16.6% Secondary and Exploratory Analyses Primary Endpoint Results: 16.6% median reduction in TSC-associated se

  14. Slide 14: Phase 3 Protocol Refinements Informed by Phase 2 Tolerability

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I Phase 3 Protocol Refinements Informed by Phase 2 Tolerability 14 Phase 3 Slower titration initially, designed to optimize tolerability and improve efficacy No (n=6) Yes (n=17) 0 5 10 15 20 25 30 Somnolence-related AE Percentreduction in TSC-associ

  15. Slide 15: Phase 3 Trial Overview

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I Phase 3 Trial Overview 15 ► Enrollment: ~128 patients, targeting sites in the U.S., Western Europe, Canada, Israel, Australia and China • 90% powered to detect a 25% treatment difference • Statistical significance could be achieved with a treatmen

  16. Slide 16: TrustTSC Baseline Demographics

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I TrustTSC Baseline Demographics* 16 Age (mean [min-max]) 15 [1-50] Gender 52% male 48% female Failed Therapies* (mean) 4.8 Baseline Seizure Rate (median, per 28 days) 50 DB Discontinuation Rate** ~7% 2 discontinuations (<2%) due to somnolence-relat

  17. Slide 17: Anticipated Commercial Expansion into Tuberous Sclerosis Complex

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I 17 Influential Advocacy Community Reflects the values and priorities of the TSC community and addresses the unique challenges associated with rare genetic epilepsy Significant Market Opportunity TSC can be readily diagnosed, and a substantial port

  18. Slide 18: Unlocking a 4-5x Growth Opportunity for ZTALMY in TSC

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I Unlocking a 4-5x Growth Opportunity for ZTALMY® in TSC 18 1TSC Alliance; 2Marinus ZS Opportunity Assessment, 2020 Market Research; 3Curatolo P - Epilepsy in TSC: Findings from the TOSCA Study; 4Chu-Shore CJ et al.The natural history of epilepsy in

  19. Slide 19: Plans to Leverage Existing ZTALMY Infrastructure in TSC

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I Plans to Leverage Existing ZTALMY® Infrastructure Expected to Yield Significant Returns in TSC 19 19 COMMERCIAL INFRASTRUCTURE Addition of 12-16 RAMs to reach key targets, including 17 TSC COEs MARKET POSITIONING Distinct TSC positioning: First Ph

  20. Slide 20: Significant Growth Potential with Expansion into Larger Indications

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I Significant Growth Potential with Expansion into Larger Indications 20 ~12.7k refractory patients in the U.S. ~48k patients in the U.S. ~2k patients in the U.S. CDKL5 Deficiency Disorder Approved in U.S. in 2022 Tuberous Sclerosis Complex Potentia

  21. Slide 21: Second Generation Product Development

    Second Generation Product Development

  22. Slide 22: Second Generation Ganaxolone - Prodrug Goals

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I Second Generation Ganaxolone - Prodrug 22 Goals Target Oral Pharmacokinetic Profile Increase efficacy Consistent delivery to achieve target plasma concentration Improve tolerability Optimize PK profile to reduce Cmax-related adverse effects Reduce

  23. Slide 23: Status Epilepticus

    Status Epilepticus

  24. Slide 24: Status Epilepticus Overview

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I Status Epilepticus Overview 24 Status Epilepticus = Condition resulting from either the failure of the mechanisms responsible for seizure termination or from the initiation of mechanisms which lead to: • abnormally prolonged seizures (after time p

  25. Slide 25: Pharmacokinetics/Pharmacodynamics Well Suited for Acute SE Treatment

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I Pharmacokinetics/Pharmacodynamics Well Suited for Acute SE Treatment 25 Experimental PK – plasma and brain1 Brain and plasma concentration after ganaxolone 3 mg/kg IM in mice Human PD – EEG changes2 EEG bispectral index in healthy volunteers follo

  26. Slide 26: RAISE: Phase 3 Trial in Refractory Status Epilepticus

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I RAISE: Phase 3 Trial in Refractory Status Epilepticus 26 STUDY POPULATION INTERVENTION CO-PRIMARY ENDPOINTS KEY SECONDARY ENDPOINTS Onset of Action: Proportion of patients with SE cessation within 30 minutes Durability of Effect: Proportion of pat

  27. Slide 27: RAISE Topline Results: Baseline Characteristics

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I RAISE Topline Results: Baseline Characteristics 27 *Safety population (unless otherwise noted) A ITT population Baseline Characteristics* Placebo (n = 49) IV Ganaxolone (n = 51) Age (years), median (range) 59 (15 – 90) 60 (16 – 88) Male sex, no. (

  28. Slide 28: RAISE Topline Results: Co-Primary Endpoints

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I RAISE Topline Results: Co-Primary Endpoints 28 Proportion of patients with no progression to IV anesthesia for 36 hours Proportion of patients with SE cessation within 30 minutes without medications for the acute treatment of SE IV Ganaxolone (n =

  29. Slide 29: RAISE Topline Results: EEG Secondary Endpoint

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I RAISE Topline Results: EEG Secondary Endpoint 29 Median percent reduction in EEG seizure burden* Ganaxolone (N=43) Placebo (N=39) EEG seizure burden is a potential measure of durability of effect *Data reported is the pre-anesthesia seizure burden

  30. Slide 30: Approach to SRSE

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I ► SRSE-specific dosing approach • ↓Cmax but ↑ AUC • 3-month oral wean • Ganaxolone 833mg/day x48h ➛ 1,050mg/day x 168h • Captisol® 50gm/day ➛ 63gm/day Approach to SRSE 30 31 patients with SRSE treated with IV ganaxolone as of August 2024 14 with r

  31. Slide 31: Financial Update

    Financial Update

  32. Slide 32: Financial Overview

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I Financial Overview 32 Analyst Coverage*: Cantor Fitzgerald: Charles C. Duncan, Ph.D. T.D. Cowen: Joseph Thome, Ph.D. H.C. Wainwright & Co: Douglas Tsao Jefferies: Andrew Tsai JMP Securities: Jason N. Butler, Ph.D. Ladenburg Thalmann: Michael Higgi

  33. Slide 33: Intellectual Property

    Intellectual Property

  34. Slide 34: Multiple Layers Of Potential Protection

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I Multiple Layers Of Potential Protection 34 Orphan drug designations for CDD and PCDH19 provide 7 and 10 years regulatory exclusivity in U.S. and EU, respectively. Orphan drug designation for SE provides 7 years regulatory exclusivity in U.S. U.S.

  35. Slide 35: Appendix

    Appendix (® MARINUS

  36. Slide 36: A Comprehensive Commercial Strategy to Grow the ZTALMY Brand

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I A Comprehensive Commercial Strategy to Grow the ZTALMY® Brand 36 Patient identification Activate the caregiver community Focused education to HCPs to establish ZTALMY as the standard of care for CDD seizure management Continuously enhance the pati

  37. Slide 37: Average Ganaxolone Levels Correlate with Seizure Reduction

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I Average Ganaxolone Levels Correlate with Seizure Reduction 37 • Logarithms of plasma ganaxolone level and percentage change in major motor seizure frequency were negatively correlated • Patients in the Medium and High ganaxolone level groups had a

Marinus Pharmaceuticals — Investor Presentation (August 2024) on 6ix